We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+22.19%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$645M
AUM Growth
+$73.5M
Cap. Flow
-$82.4M
Cap. Flow %
-12.78%
Top 10 Hldgs %
83.04%
Holding
31
New
5
Increased
3
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.5M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.76M
3
ARRY
Array Biopharma Inc
ARRY
+$4.7M
4
TRVN
Trevena, Inc.
TRVN
+$2.75M
5
VXRT
Vaxart
VXRT
+$2.45M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$35.4M
2
CYTK icon
Cytokinetics
CYTK
+$20.5M
3
RIGL icon
Rigel Pharmaceuticals
RIGL
+$19.1M
4
XNCR icon
Xencor
XNCR
+$7.5M
5
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$3.66M

Sector Composition

Rank Sector Weight
1 Healthcare 71.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$5.94B
$141M 21.86%
3,360,555
-849,179
-20% -$35.4M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$614M
$115M 17.77%
11,107,786
-325,539
-3% -$3.66M
CCXI
3
DELISTED
ChemoCentryx, Inc.
CCXI
$51.7M 8.01%
7,796,516
– –
AMGN icon
4
PUT
Amgen
AMGN
$209B
$45.1M 6.99%
+365,400
New +$44.3M
ARRY
5
DELISTED
Array Biopharma Inc
ARRY
$39.9M 6.18%
8,486,927
+933,838
+12% +$4.7M
OMED
6
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$33.3M 5.16%
989,778
-100,700
-9% -$3.39M
GYRE icon
7
Gyre Therapeutics
GYRE
$648M
$29.3M 4.54%
7,837
– –
CASC
8
DELISTED
Cascadian Therapeutics, Inc.
CASC
$26.9M 4.17%
1,500,296
– –
FPRX
9
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$22.3M 3.46%
1,136,000
+675,000
+146% +$11.5M
TBRA
10
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$20.8M 3.22%
184,343
– –
RCPT
11
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$18.9M 2.93%
450,800
+134,108
+42% +$5.76M
QLTI
12
DELISTED
QLT Inc
QLTI
$13.2M 2.04%
2,370,263
– –
RIGL icon
13
Rigel Pharmaceuticals
RIGL
$704M
$10M 1.55%
257,671
-536,651
-68% -$19.1M
ARQL
14
DELISTED
Arqule Inc
ARQL
$5.02M 0.78%
2,449,387
-375,000
-13% -$840K
PTN
15
Palatin Technologies
PTN
$13.9M
$3.46M 0.54%
2,248
-1,912
-46% -$2.48M
TRVN
16
DELISTED
Trevena, Inc.
TRVN
$2.75M 0.43%
+560
New +$2.75M
VXRT
17
DELISTED
Vaxart
VXRT
$2.66M 0.41%
+39,627
New +$2.45M
SPHS
18
DELISTED
Sophiris Bio, Inc.
SPHS
$2M 0.31%
600,000
– –
AKAO
19
DELISTED
Achaogen Inc
AKAO
$1.93M 0.3%
+125,000
New +$2.16M
ANTH
20
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.88M 0.29%
69,953
– –
BLRX
21
BioLineRX
BLRX
$11.7M
$1.78M 0.28%
+1,333
New +$2.19M
RGLS
22
DELISTED
Regulus Therapeutics
RGLS
$1.67M 0.26%
1,542
-405
-21% -$449K
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.43M 0.22%
74,900
-59,417
-44% -$1.23M
BIND
24
DELISTED
BIND THERAPEUTICS INC
BIND
$1.39M 0.22%
116,000
-34,000
-23% -$444K
CYTK icon
25
Cytokinetics
CYTK
$10.9B
$1M 0.16%
105,705
-2,263,200
-96% -$20.5M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2014 Portfolio in Review

As of Q1 2014, BVF Inc held 31 positions worth $645M, up 13% from $572M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

BVF Inc withdrew a net $82.4M in Q1 2014, closing 3 positions and reducing 10 holdings. Its most notable exit was Xencor, an estimated $7.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 77% a quarter earlier.

Against the trend, BVF Inc opened a new position in Trevena, Inc. worth $2.75M.

  • BVF Inc's largest Q1 2014 buy was Trevena, Inc.: 560 shares worth $2.75M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q1 2014, an estimated $11.5M increase.
  • BVF Inc's biggest Q1 2014 reduction was Ligand Pharmaceuticals, cutting an estimated $35.4M.
  • BVF Inc fully exited Xencor in Q1 2014, selling an estimated $7.5M.
  • BVF Inc's ten largest holdings make up 83% of its $645M portfolio in Q1 2014.
  • BVF Inc opened 5 new positions and closed 3 in Q1 2014.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $645M.

Based on BVF Inc's 13F filing for Q1 2014, filed 15 May 2014.